Secondly, CEACAM6 has been shown to modulate the cytotoxic effects of conventional chemotherapeutics such as gemcitabine in pancreatic cancer cell lines[9] and in the present study we showed that CEACAM6 could mediate sensitivity to new targeted agents such as the PI3K inhibitor, BGT226. The gene discussed is CEACAM6; the disease is familial pancreatic carcinoma.